SynAct Pharma Reports Additional Results of the P-IIb (EXPAND) Study Supporting the Development of Resomelagonin for Rheumatoid Arthritis (RA)
Shots:
- SynAct conducted a post-hoc analysis of the EXPAND study for resomelagon (100mg, QD, oral) in treatment naïve rheumatoid arthritis (RA) patients who had elevated baseline C-reactive protein (CRP> 3mg/L)
- A subset analysis, to support the assessment, conducted in the participants with elevated baseline CRP recruited after 6mos. of their diagnosis for RA revealed that resomelagon (100mg, QD) showed a consistent & favorable response vs PBO
- The findings, at 12wks., of (EXPAND) study depicted an ACR20 of 71% in 23/28 patients vs 54% in 14/27 of them, a difference in the reduction in CDAI was 24.6 vs 14.7 points, reduction in DAS28-CRP was 1.9 vs 1.2 points and reduction in HAQ disability index was 0.69 vs 0.31 points
Ref: SynAct Pharma | Image: SynAct Pharma
Related News:- Dr. Reddy Reports the Completion of the P-I Study of DRL_TC, a Proposed Biosimilar of Tocilizumab for Rheumatoid Arthritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
